Targeted therapy in thyroid cancer Journal Article
| Authors: | Nixon, I. J.; Shaha, A. R.; Tuttle, M. R. |
| Article Title: | Targeted therapy in thyroid cancer |
| Abstract: | Purpose of Review: Recent advances in the understanding of the biological basis for thyroid cancer have identified molecular changes in thyroid cancer cells. These changes form the basis for targeted therapies, which have been investigated with some success in patients with advanced, inoperable thyroid cancers and are the subject of this review. Recent Findings: For patients with advanced differentiated thyroid cancers, sorafenib, selumetinib, pazopanib and sunitinib have been investigated with promising results. In the setting of advanced medullary thyroid cancer, vandetanib now has FDA approval, whereas sorafenib, sunitinib and cabozantinib have shown activity in early studies. For patients with anaplastic thyroid cancer, no targeted therapy has been proven to be effective in vivo, although preclinical work on various kinase inhibitors has shown promise. Despite the potential for disease response, significant cardiac, gastrointestinal and skin-related side effects are reported for all therapies, limiting their application outside the setting of incurable disease. Summary: Inoperable thyroid cancer still has a poor prognosis, however, the introduction of targeted therapies offers the hope of longer quality of meaningful life for this small group of patients. © 2013 Lippincott Williams & Wilkins. |
| Keywords: | signal transduction; mitogen activated protein kinase; cancer chemotherapy; cancer survival; treatment response; gene mutation; review; squamous cell carcinoma; sorafenib; cisplatin; doxorubicin; placebo; sunitinib; advanced cancer; cancer combination chemotherapy; diarrhea; drug dose reduction; antineoplastic agents; drug approval; paclitaxel; cancer patient; metastasis; progression free survival; quality of life; map kinase signaling system; bleeding; gastrointestinal symptom; heart disease; antineoplastic activity; protein kinase inhibitors; drug fatality; lung metastasis; cancer cell; tipifarnib; pazopanib; vandetanib; brain metastasis; sepsis; targeted therapy; skin disease; thyroid cancer; thyroid neoplasms; inoperable cancer; hand foot syndrome; alopecia; b raf kinase; follicular carcinoma; thyroid medullary carcinoma; molecularly targeted therapy; differentiated thyroid cancer; medullary thyroid cancer; molecular targeted therapy; anaplastic thyroid cancer; kinase inhibitors; selumetinib; cabozantinib; advanced thyroid cancer |
| Journal Title: | Current Opinion in Otolaryngology & Head and Neck Surgery |
| Volume: | 21 |
| Issue: | 2 |
| ISSN: | 1068-9508 |
| Publisher: | Lippincott Williams & Wilkins |
| Date Published: | 2013-04-01 |
| Start Page: | 130 |
| End Page: | 134 |
| Language: | English |
| PROVIDER: | scopus |
| PUBMED: | 23435040 |
| DOI: | 10.1097/MOO.0b013e32835aa2c2 |
| DOI/URL: | |
| Notes: | --- - "Export Date: 1 May 2013" - "CODEN: COOSF" - ":doi 10.1097/MOO.0b013e32835aa2c2" - ": Chemicals/CAScabozantinib, 1140909-48-3, 849217-68-1, 942407-59-2; cisplatin, 15663-27-1, 26035-31-4, 96081-74-2; doxorubicin, 23214-92-8, 25316-40-9; mitogen activated protein kinase, 142243-02-5; paclitaxel, 33069-62-4; pazopanib, 444731-52-6, 635702-64-6; selumetinib, 606143-52-6, 865610-79-3, 943332-08-9; sorafenib, 284461-73-0; sunitinib, 341031-54-7, 557795-19-4; tipifarnib, 192185-68-5, 192185-72-1; vandetanib, 338992-00-0, 338992-48-6, 443913-73-3" - "Source: Scopus" |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work